We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Identification of an HLA-A<sup>*</sup>0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.
- Authors
Kiessling, A; Stevanovic, S; Füssel, S; Weigle, B; Rieger, M A; Temme, A; Rieber, E P; Schmitz, M
- Abstract
The development of T-cell-based immunotherapies of cancer largely depends on the availability of tumour-associated antigens capable of eliciting tumour-directed cytotoxic T-cell responses. In prostate cancer, the number of antigens defined as suitable targets of cytotoxic T lymphocytes (CTLs) is still limited. Recently, prostein was identified as a transmembrane protein that is highly restricted to prostate tissues. In our study, prostein transcripts were found to be abundant in both malignant and nonmalignant prostate tissue samples. To identify immunogenic CD8+ T-cell epitopes, human leucocyte antigen-A*0201-binding peptides were selected from the amino-acid sequence of prostein and were used for the in vitro stimulation of CD8+ T lymphocytes. Specific CTLs were raised against the prostein-derived peptide CLAAGITYV that were capable of lysing prostate cancer cells, indicating that this peptide is naturally generated by tumour cells. Our data suggest that prostein is a suitable candidate to be included in a T-cell-based immunotherapy of prostate cancer.British Journal of Cancer (2004) 90, 1034-1040. doi:10.1038/sj.bjc.6601642 www.bjcancer.com
- Publication
British Journal of Cancer, 2004, Vol 90, Issue 5, p1034
- ISSN
0007-0920
- Publication type
Academic Journal
- DOI
10.1038/sj.bjc.6601642